Approval of this product under the PEPFAR program completes Strides’ qualification to all major markets and donor programs including Global Fund and South Africa
Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
The product is being launched in August 2023
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
Take proper precautions and seek timely treatment!
Subscribe To Our Newsletter & Stay Updated
